Acute Myeloid Leukemia Market Report and Forecast 2025-2034
Description
The acute myeloid leukemia market was valued at USD 3.53 Billion in 2024, driven by the growing focus on personalized medicine and immuno-oncology therapies across 8 major markets. The market is anticipated to grow at a CAGR of 10.44% during the forecast period of 2025-2034, with the values likely to reach USD 9.53 Billion by 2034.
Acute Myeloid Leukemia Market Overview
Acute myeloid leukemia (AML) is a blood cancer that starts in the bone marrow and primarily affects adults. The average age for diagnosis of the disease is 69 years. The rising incidence, particularly among older adults, is propelling a surge in the demand for advanced treatment regimens for the condition. The market growth is spurred by multiple factors, such as developments in immunotherapy, personalized medicine, and early diagnosis. During the forecast period, the market value is expected to increase due to investments by pharmaceutical companies in innovative therapies.
Acute Myeloid Leukemia Market Growth Drivers
Rising Prevalence of Acute Myeloid Leukemia Drives Market Growth
The acute myeloid leukemia (AML) prevalence rate has been increasing, with about 20,800 new cases and 11,220 deaths from acute myeloid leukemia predicted by the American Cancer Society in 2024. AML accounts for about 1 in 3 leukemias in adults, presenting with an average age of diagnosis of around 69 years. This increasing prevalence, especially among adults, calls for more effective therapeutics creating novel opportunities in the market while pharmaceutical companies continue developing innovative new therapies for effective management.
Acute Myeloid Leukemia Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
Increasing Drug Approvals from Regulatory Authorities
The increasing approvals of newly developed drugs by regulatory authorities like EMA and the United States FDA are some of the major trends in the market. Such approvals are expected to address the unmet needs of a wider section of the audience.
Growth in Demand for Personalized Medicine
The increasing demand for personalized medicine is another trend in the market. An increasing knowledge of human physiology, technological improvements and knowledge of biomarkers and genomics has allowed special drugs to be produced according to the genetic map of an individual, which in turn leads to precise treatment.
Surge in Funding and Investments
There has been an increase in fundings and investments from governments and non-governmental organizations to the pharma companies and research centers, with an aim to develop new products for the cure of acute myeloid leukemia. Such investments are poised to fuel the market value in the forecast period.
Growing Need for Early Diagnostics
Discovering new treatments using artificial intelligence for treating the condition is a notable market trend. The early diagnosis of acute myeloid leukaemia and increased efforts in spreading awareness of the disease are expected to boost market growth in the coming years.
Acute Myeloid Leukemia Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type:
Market Segmentation Based on the Treatment Type Set to Witness Substantial Growth
Based on the treatment type, the market is segmented into chemotherapy (anti-metabolites, alkylating agents, anthracycline drugs, others), targeted therapy, immunotherapy, and others. Among these, immunotherapy is expected to lead the market, driven by immune checkpoint inhibitors like Ipilimumab (Yervoy) and Atezolizumab (Tecentriq), which are expected to enhance immuno-oncology positively in the forecast period. The growing advancements in molecular biology and the increasing demand for personalized medicine are anticipated to bolster market growth during the forecast period.
Acute Myeloid Leukemia Market by Region
Based on the region, the market report offers insights intothe United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. Among these, the United States is anticipated to lead the market, owing to the existence of major pharmaceutical firms and substantial healthcare expenditure. Robust research efforts and governmental backing for cancer studies are aiding the expansion of the regional market.
Leading Players in the Acute Myeloid Leukemia Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bristol-Myers Squibb Company
Headquartered in New York and a leading player in the field of immuno-oncology research, Bristol-Myers Squibb develops numerous drug types, including Reblozyl (luspatercept) and Opdivo (nivolumab). Opdivo is a PD-1 inhibitor developed for activating immunity by binding to the PD-1 receptor, which allows the immune system to detect and destroy tumor cells.
F. Hoffmann-La Roche AG
F. Hoffmann-La Roche Ltd. is a global leader in pharmaceutical and diagnostics based in Basel, Switzerland, and was established in 1896. Roche’s Venclexta (venetoclax) is an oral BCL-2 inhibitor that has gained considerable ground to be in combination with other drugs like azacitidine in elderly patients with AML.
Pfizer Inc.
The company was founded in New York in 1849. The development of Bosulif (bosutinib), a tyrosine kinase inhibitor, by Pfizer Inc. contributed to the AML landscape. Bosulif is under investigation for the treatment of select subsets of AML, although it is primarily used for chronic myelogenous leukemia (CML).
Novartis AG
Novartis AG is a global pharmaceutical company based in Basel, Switzerland. The focus of this company has been on Kymriah, a CAR-T cell therapy that holds great hope in treating various forms of leukemia, among which, AML has shown to be effective in clinical trials.
Other companies include AbbVie Inc., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Agios Pharmaceuticals, Inc., Jazz Pharmaceuticals plc., and Amgen Inc., among others.
Key Questions Answered in the Acute Myeloid Leukemia Market
Acute Myeloid Leukemia Market Overview
Acute myeloid leukemia (AML) is a blood cancer that starts in the bone marrow and primarily affects adults. The average age for diagnosis of the disease is 69 years. The rising incidence, particularly among older adults, is propelling a surge in the demand for advanced treatment regimens for the condition. The market growth is spurred by multiple factors, such as developments in immunotherapy, personalized medicine, and early diagnosis. During the forecast period, the market value is expected to increase due to investments by pharmaceutical companies in innovative therapies.
Acute Myeloid Leukemia Market Growth Drivers
Rising Prevalence of Acute Myeloid Leukemia Drives Market Growth
The acute myeloid leukemia (AML) prevalence rate has been increasing, with about 20,800 new cases and 11,220 deaths from acute myeloid leukemia predicted by the American Cancer Society in 2024. AML accounts for about 1 in 3 leukemias in adults, presenting with an average age of diagnosis of around 69 years. This increasing prevalence, especially among adults, calls for more effective therapeutics creating novel opportunities in the market while pharmaceutical companies continue developing innovative new therapies for effective management.
Acute Myeloid Leukemia Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
Increasing Drug Approvals from Regulatory Authorities
The increasing approvals of newly developed drugs by regulatory authorities like EMA and the United States FDA are some of the major trends in the market. Such approvals are expected to address the unmet needs of a wider section of the audience.
Growth in Demand for Personalized Medicine
The increasing demand for personalized medicine is another trend in the market. An increasing knowledge of human physiology, technological improvements and knowledge of biomarkers and genomics has allowed special drugs to be produced according to the genetic map of an individual, which in turn leads to precise treatment.
Surge in Funding and Investments
There has been an increase in fundings and investments from governments and non-governmental organizations to the pharma companies and research centers, with an aim to develop new products for the cure of acute myeloid leukemia. Such investments are poised to fuel the market value in the forecast period.
Growing Need for Early Diagnostics
Discovering new treatments using artificial intelligence for treating the condition is a notable market trend. The early diagnosis of acute myeloid leukaemia and increased efforts in spreading awareness of the disease are expected to boost market growth in the coming years.
Acute Myeloid Leukemia Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type:
- Myeloblastic Leukemia
- Promyelocytic Leukemia
- Monocytic Leukemia
- Myelomonocytic Leukemia
- Others
- Chemotherapy
- Anti-metabolites
- Alkylating agents
- Anthracycline drugs
- Others
- Targeted Therapy
- Immunotherapy
- Others
- Oral
- Parenteral
- Others
- Hospitals
- Specialty Centers
- Homecare Settings
- Ambulatory Care Centers
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on the Treatment Type Set to Witness Substantial Growth
Based on the treatment type, the market is segmented into chemotherapy (anti-metabolites, alkylating agents, anthracycline drugs, others), targeted therapy, immunotherapy, and others. Among these, immunotherapy is expected to lead the market, driven by immune checkpoint inhibitors like Ipilimumab (Yervoy) and Atezolizumab (Tecentriq), which are expected to enhance immuno-oncology positively in the forecast period. The growing advancements in molecular biology and the increasing demand for personalized medicine are anticipated to bolster market growth during the forecast period.
Acute Myeloid Leukemia Market by Region
Based on the region, the market report offers insights intothe United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. Among these, the United States is anticipated to lead the market, owing to the existence of major pharmaceutical firms and substantial healthcare expenditure. Robust research efforts and governmental backing for cancer studies are aiding the expansion of the regional market.
Leading Players in the Acute Myeloid Leukemia Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bristol-Myers Squibb Company
Headquartered in New York and a leading player in the field of immuno-oncology research, Bristol-Myers Squibb develops numerous drug types, including Reblozyl (luspatercept) and Opdivo (nivolumab). Opdivo is a PD-1 inhibitor developed for activating immunity by binding to the PD-1 receptor, which allows the immune system to detect and destroy tumor cells.
F. Hoffmann-La Roche AG
F. Hoffmann-La Roche Ltd. is a global leader in pharmaceutical and diagnostics based in Basel, Switzerland, and was established in 1896. Roche’s Venclexta (venetoclax) is an oral BCL-2 inhibitor that has gained considerable ground to be in combination with other drugs like azacitidine in elderly patients with AML.
Pfizer Inc.
The company was founded in New York in 1849. The development of Bosulif (bosutinib), a tyrosine kinase inhibitor, by Pfizer Inc. contributed to the AML landscape. Bosulif is under investigation for the treatment of select subsets of AML, although it is primarily used for chronic myelogenous leukemia (CML).
Novartis AG
Novartis AG is a global pharmaceutical company based in Basel, Switzerland. The focus of this company has been on Kymriah, a CAR-T cell therapy that holds great hope in treating various forms of leukemia, among which, AML has shown to be effective in clinical trials.
Other companies include AbbVie Inc., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Agios Pharmaceuticals, Inc., Jazz Pharmaceuticals plc., and Amgen Inc., among others.
Key Questions Answered in the Acute Myeloid Leukemia Market
- What was the acute myeloid leukemia market value in 2024?
- What is the acute myeloid leukemia market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the disease type?
- What is the market breakup based on the treatment type?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on the end user?
- What are the major factors aiding the acute myeloid leukemia market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major acute myeloid leukemia market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the acute myeloid leukemia market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What are the current treatment options for myeloblastic leukemia in the market?
- What is the significance of alkylating agents in leukemia therapy?
- What are the benefits of parenteral administration in acute myeloid leukemia therapies?
- How do hospitals manage acute myeloid leukemia treatments compared to specialty centres?
- How does the acute myeloid leukemia treatment market differ across EU-4 countries and the UK?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Acute Myeloid Leukemia Market Overview – 8 Major Markets
- 3.1 Acute Myeloid Leukemia Market Historical Value (2018-2024)
- 3.2 Acute Myeloid Leukemia Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Acute Myeloid Leukemia Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Acute Myeloid Leukemia Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 EU4
- 7.2.4 India
- 7.2.5 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 EU4
- 7.3.4 India
- 7.3.5 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 EU4
- 7.4.4 India
- 7.4.5 Japan
- 8 Acute Myeloid Leukemia Market Landscape – 8 Major Markets
- 8.1 Acute Myeloid Leukemia Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Acute Myeloid Leukemia Market: Product Landscape
- 8.2.1 Analysis by Disease Type
- 8.2.2 Analysis by Treatment Type
- 8.2.3 Analysis by Route of Administration
- 9 Acute Myeloid Leukemia Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Acute Myeloid Leukemia Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Acute Myeloid Leukemia Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Acute Myeloid Leukemia Market (2018-2034) by Disease Type
- 12.1.1 Market Overview
- 12.1.2 Myeloblastic Leukemia
- 12.1.3 Promyelocytic Leukemia
- 12.1.4 Monocytic Leukemia
- 12.1.5 Myelomonocytic Leukemia
- 12.1.6 Others
- 12.2 Acute Myeloid Leukemia Market (2018-2034) by Treatment Type
- 12.2.1 Market Overview
- 12.2.2 Chemotherapy
- 12.2.2.1 Anti-metabolites
- 12.2.2.2 Alkylating agents
- 12.2.2.3 Anthracycline drugs
- 12.2.2.4 Others
- 12.2.3 Targeted Therapy
- 12.2.4 Immunotherapy
- 12.2.5 Others
- 12.3 Acute Myeloid Leukemia Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.3.4 Others
- 12.4 Acute Myeloid Leukemia Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals
- 12.4.3 Specialty Centers
- 12.4.4 Homecare Settings
- 12.4.5 Ambulatory Care Centers
- 12.4.6 Others
- 12.5 Acute Myeloid Leukemia Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Acute Myeloid Leukemia Market (218-2034)
- 13.1 United States Acute Myeloid Leukemia Market (2018-2034) by Disease Type
- 13.1.1 Market Overview
- 13.1.2 Myeloblastic Leukemia
- 13.1.3 Promyelocytic Leukemia
- 13.1.4 Monocytic Leukemia
- 13.1.5 Myelomonocytic Leukemia
- 13.1.6 Others
- 13.2 United States Acute Myeloid Leukemia Market (2018-2034) by Treatment Type
- 13.2.1 Market Overview
- 13.2.2 Chemotherapy
- 13.2.2.1 Anti-metabolites
- 13.2.2.2 Alkylating agents
- 13.2.2.3 Anthracycline drugs
- 13.2.2.4 Others
- 13.2.3 Targeted Therapy
- 13.2.4 Immunotherapy
- 13.2.5 Others
- 13.3 United States Acute Myeloid Leukemia Market (2018-2034) by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Oral
- 13.3.3 Parenteral
- 13.3.4 Others
- 13.4 United States Acute Myeloid Leukemia Market (2018-2034) by End User
- 13.4.1 Market Overview
- 13.4.2 Hospitals
- 13.4.3 Specialty Centers
- 13.4.4 Homecare Settings
- 13.4.5 Ambulatory Care Centers
- 13.4.6 Others
- 14 EU-4 and United Kingdom Acute Myeloid Leukemia Market (218-2034)
- 14.1 EU-4 and United Kingdom Acute Myeloid Leukemia Market (2018-2034) by Disease Type
- 14.1.1 Market Overview
- 14.1.2 Myeloblastic Leukemia
- 14.1.3 Promyelocytic Leukemia
- 14.1.4 Monocytic Leukemia
- 14.1.5 Myelomonocytic Leukemia
- 14.1.6 Others
- 14.2 EU-4 and United Kingdom Acute Myeloid Leukemia Market (2018-2034) by Treatment Type
- 14.2.1 Market Overview
- 14.2.2 Chemotherapy
- 14.2.2.1 Anti-metabolites
- 14.2.2.2 Alkylating agents
- 14.2.2.3 Anthracycline drugs
- 14.2.2.4 Others
- 14.2.3 Targeted Therapy
- 14.2.4 Immunotherapy
- 14.2.5 Others
- 14.3 EU-4 and United Kingdom Acute Myeloid Leukemia Market (2018-2034) by Route of Administration
- 14.3.1 Market Overview
- 14.3.2 Oral
- 14.3.3 Parenteral
- 14.3.4 Others
- 14.4 EU-4 and United Kingdom Acute Myeloid Leukemia Market (2018-2034) by End User
- 14.4.1 Market Overview
- 14.4.2 Hospitals
- 14.4.3 Specialty Centers
- 14.4.4 Homecare Settings
- 14.4.5 Ambulatory Care Centers
- 14.4.6 Others
- 15 Japan Acute Myeloid Leukemia Market (218-2034)
- 15.1 Japan Acute Myeloid Leukemia Market (2018-2034) by Disease Type
- 15.1.1 Market Overview
- 15.1.2 Myeloblastic Leukemia
- 15.1.3 Promyelocytic Leukemia
- 15.1.4 Monocytic Leukemia
- 15.1.5 Myelomonocytic Leukemia
- 15.1.6 Others
- 15.2 Japan Acute Myeloid Leukemia Market (2018-2034) by Treatment Type
- 15.2.1 Market Overview
- 15.2.2 Chemotherapy
- 15.2.2.1 Anti-metabolites
- 15.2.2.2 Alkylating agents
- 15.2.2.3 Anthracycline drugs
- 15.2.2.4 Others
- 15.2.3 Targeted Therapy
- 15.2.4 Immunotherapy
- 15.2.5 Others
- 15.3 Japan Acute Myeloid Leukemia Market (2018-2034) by Route of Administration
- 15.3.1 Market Overview
- 15.3.2 Oral
- 15.3.3 Parenteral
- 15.3.4 Others
- 15.4 Japan Acute Myeloid Leukemia Market (2018-2034) by End User
- 15.4.1 Market Overview
- 15.4.2 Hospitals
- 15.4.3 Specialty Centers
- 15.4.4 Homecare Settings
- 15.4.5 Ambulatory Care Centers
- 15.4.6 Others
- 16 India Acute Myeloid Leukemia Market (218-2034)
- 16.1 India Acute Myeloid Leukemia Market (2018-2034) by Disease Type
- 16.1.1 Market Overview
- 16.1.2 Myeloblastic Leukemia
- 16.1.3 Promyelocytic Leukemia
- 16.1.4 Monocytic Leukemia
- 16.1.5 Myelomonocytic Leukemia
- 16.1.6 Others
- 16.2 India Acute Myeloid Leukemia Market (2018-2034) by Treatment Type
- 16.2.1 Market Overview
- 16.2.2 Chemotherapy
- 16.2.2.1 Anti-metabolites
- 16.2.2.2 Alkylating agents
- 16.2.2.3 Anthracycline drugs
- 16.2.2.4 Others
- 16.2.3 Targeted Therapy
- 16.2.4 Immunotherapy
- 16.2.5 Others
- 16.3 India Acute Myeloid Leukemia Market (2018-2034) by Route of Administration
- 16.3.1 Market Overview
- 16.3.2 Oral
- 16.3.3 Parenteral
- 16.3.4 Others
- 16.4 India Acute Myeloid Leukemia Market (2018-2034) by End User
- 16.4.1 Market Overview
- 16.4.2 Hospitals
- 16.4.3 Specialty Centers
- 16.4.4 Homecare Settings
- 16.4.5 Ambulatory Care Centers
- 16.4.6 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Novartis AG
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Development
- 23.2.5 Certifications
- 23.3 AbbVie Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Development
- 23.3.5 Certifications
- 23.4 Bristol Myers Squibb Company
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Development
- 23.4.5 Certifications
- 23.5 Pfizer Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Development
- 23.5.5 Certifications
- 23.6 F. Hoffmann-La Roche AG.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Development
- 23.6.5 Certifications
- 23.7 Astellas Pharma Inc.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Development
- 23.7.5 Certifications
- 23.8 Daiichi Sankyo Co., Ltd.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Development
- 23.8.5 Certifications
- 23.9 Agios Pharmaceuticals, Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Development
- 23.9.5 Certifications
- 23.10 Jazz Pharmaceuticals plc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Development
- 23.10.5 Certifications
- 23.11 Amgen Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Development
- 23.11.5 Certifications
- 24 Acute Myeloid Leukemia Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
